Trending News

Blog Post

Market

Orbimed Advisors lowered stake in Graybug Imaginative and prescient, Inc. By Investing.com 



© Reuters. Orbimed Advisors lowered stake in Graybug Imaginative and prescient, Inc.

On the twenty fifth of March, Orbimed Advisors bought 313 thousand Graybug Imaginative and prescient, Inc. (GRAY) shares for $1.9 million at a mean value of $6.16 per share.
Shares of Graybug Imaginative and prescient, Inc. are down -11.53% for the reason that transaction.

Orbimed Advisors’s holding in Graybug Imaginative and prescient, Inc. decreased to about 4.2 million shares with the transaction.

Orbimed Advisors first purchased Graybug Imaginative and prescient, Inc. inventory within the third quarter of 2020.
Orbimed Advisors additionally owns Biogen Inc (NASDAQ:), Kinnate Biopharma Inc. (KNTE), Arcutis Biotherapeutics, Inc. (NASDAQ:) and Eledon Prescription drugs, Inc. (ELDN).
Graybug Imaginative and prescient, Inc. is its quantity twenty eight place by variety of shares and market worth amongst prescription drugs shares.

In distinction, California State Academics Retirement System and Citigroup (NYSE:) launched GRAY shares to their portfolio.

Orbimed Advisors has additionally not too long ago bought all their shares in ObsEva SA (NASDAQ:).
Orbimed Advisors additionally lowered their share in Theravance Biopharma, Inc. (NASDAQ:), Otonomy, Inc. (NASDAQ:), Kala Prescription drugs, Inc. (NASDAQ:), Arcutis Biotherapeutics, Inc., Oric Prescription drugs, Inc. (ORIC) and Prelude Therapeutics Incorporat (PRLD).
The entire worth of the shares bought is estimated at round $88 million.

As well as, Orbimed Advisors established new holdings in VistaGen Therapeutics, Inc. (NASDAQ:).
Orbimed Advisors additionally added to their share in Aeglea BioTherapeutics, Inc. (AGLE).
The entire worth of the shares purchased is estimated at round $27 million.

Orbimed Advisors additionally bought all their shares in Prevail Therapeutics Inc . (NASDAQ:).
This asset alone constituted 1.8% of their pre-sale portfolio.
Orbimed Advisors additionally lowered their share in Fluidigm Corp (NASDAQ:), Prothena Company plc (PRTA), Larimar Therapeutics, Inc. (LRMR), Xenon (NASDAQ:) Prescription drugs Inc. (XENE), Strongbridge Biopharma plc (NASDAQ:), Harpoon Therapeutics, Inc. (NASDAQ:), Turning Level Therapeutics, Inc (NASDAQ:), Passage Bio, Inc. (PASG) and Adicet Bio, Inc. (ACET).
The entire worth of the shares bought is estimated at round $482 million.

As well as, Orbimed Advisors added to their share in Adverum Biotechnologies Inc (NASDAQ:), Corvus Prescription drugs Inc (NASDAQ:), MeiraGTx Holdings plc (MGTX), X4 Prescription drugs, Inc. (NASDAQ:) and Utilized Therapeutics, Inc. (NASDAQ:).
The entire worth of the shares purchased is estimated at round $33 million.

Disclaimer: Fusion Media want to remind you that the information contained on this web site shouldn’t be essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs will not be supplied by exchanges however reasonably by market makers, and so costs is probably not correct and should differ from the precise market value, which means costs are indicative and never acceptable for buying and selling functions. Due to this fact Fusion Media doesn`t bear any duty for any buying and selling losses you may incur on account of utilizing this information.

Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury on account of reliance on the data together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding types potential.





Supply hyperlink

Related posts

Leave a Reply

Required fields are marked *